Basecamp Research Maps Biology for AI-Designed Medicine

Basecamp Research is building an AI system for therapeutic design from a source most biological models barely touch: the genetic record of life outside the usual public databases. The London company collects and contextualizes biological data through field partnerships, trains its EDEN foundation models on that data, and uses the models to design proteins and genetic medicines.

Co-founders Glen Gowers and Oliver Vince lead the company, with Phil Lorenz as CTO, John Finn as CSO, and Richard Pearce as CBO. Basecamp Research is headquartered in London and operates an office and lab in Cambridge, Massachusetts.

The company matters now because it is crossing the line between model builder and medicine developer. A new $140M Series C gives Basecamp more room to advance six AI-designed therapeutic programs, but the real test is no longer whether EDEN can produce interesting molecules. It is whether those molecules can survive preclinical development and eventually meet the evidence standard of medicine.

About Basecamp Research

The founding story began on Iceland's Vatnajökull ice cap in 2019. Gowers, Vince, and expedition partner John-Henry Charles were collecting and sequencing biological samples when the size of the missing-data problem became difficult to ignore. Public repositories captured only a narrow portion of nature's genetic diversity, leaving biological AI to learn from a compressed version of life.

Basecamp Research turned that observation into a data supply chain. The company works with biodiversity organizations across more than 30 countries and all seven continents, using access-and-benefit-sharing agreements designed to return value to the communities and institutions stewarding those environments.

Its current website reports more than 100B novel genes and more than 100T biological tokens in BaseData. Those are company-reported figures, but they explain the architecture of the business. Basecamp does not treat data as a static download. It treats collection, provenance, environmental context, and partner relationships as infrastructure.

How BaseData and EDEN Work Together

BaseData is the raw material. EDEN is the model layer. Basecamp Research describes EDEN as a family of biological foundation models trained on evolutionary genomic data, with a flagship model containing 28B parameters.

The aim is to learn not only which biological sequences exist, but why evolution preserved them and how they interact with surrounding organisms and environments. That context can help a model move from predicting biological structure toward generating candidates for specific therapeutic tasks.

Microsoft's current case study shows what that requires operationally. An earlier EDEN training effort processed 9.7T nucleotides from one million newly sequenced species while Basecamp used Azure infrastructure for genome assembly, annotation, storage, orchestration, and model training. Field science may supply the raw discovery, but industrial compute turns it into training material.

Basecamp reports laboratory or preclinical results in gene insertion, antimicrobial peptide design, and microbiome generation. Its website says EDEN's therapeutic platforms now span gene insertion, gene editing, and peptide design. None of that is patient evidence. The distinction is not paperwork. It is the distance between a promising biological instruction and a medicine that can be manufactured, delivered, measured, and trusted.

The Therapeutic Pipeline Changes the Stakes

Basecamp Research's new $140M Series C is financing that transition. S32 led the oversubscribed round, and Reuters reported an $800M valuation. The official announcement says the company will train a new EDEN generation, advance six therapeutic programs, begin with in vivo cell therapy, and expand pharmaceutical partnerships.

The investor list stretches across life sciences, frontier technology, philanthropy, and strategic infrastructure. It includes NVIDIA, Anthropic's Anthology Fund, NATO Innovation Fund, The Rockefeller Foundation, Singular, True Ventures, and other firms named in the announcement. That mix reflects what Basecamp is attempting to combine: globally sourced biology, large-scale computation, therapeutic development, and a commercial path through pharmaceutical partnerships.

The Trillion Gene Atlas adds another layer. Developed with Anthropic, Ultima Genomics, and PacBio and powered by NVIDIA infrastructure, the initiative is designed to expand Basecamp's biological dataset far beyond its current scale. The strategic question is whether each additional order of data produces a meaningful gain in therapeutic design, not merely a larger number in a press release.

Leadership Built Around Translation

Basecamp Research's leadership page shows a team organized around the handoffs ahead. Gowers brings engineering-biology training and experience at GSK. Vince combines computer science, engineering, and cancer-drug research. Lorenz leads technology across genomics, AI, and bioinformatics.

Finn brings more than 25 years in gene and cell therapy, including work at Intellia Therapeutics, Codiak Biosciences, and Tome Biosciences. Pearce joined from Biogen to lead licensing, commercial strategy, and pharmaceutical partnerships. The titles form a useful map: data and models must now move through scientific development and into partnerships capable of supporting much longer timelines.

The risk is familiar to every platform company entering drug development. A model can generate many candidates. A pipeline has to choose which ones deserve years of capital, design the right studies, solve delivery and safety, and kill weak programs early. The company will be judged by those decisions more than by model benchmarks.

Hiring Reveals the Operating Priorities

Basecamp's live careers page listed 10 full-time, on-site roles on September 23, 2026. Eight were in London and two were in Boston. The openings covered AI research engineering, bioinformatics, scientific research, production sequencing, global research partnerships, laboratory operations, technical program management, and office operations.

That mix is more revealing than a generic claim that the company is growing. Basecamp is adding people at the seams between data collection, sequencing, model development, laboratory execution, and program coordination. Those are the seams most likely to tear when a research platform begins carrying therapeutic assets.

Current job materials describe a low-ego, collaborative culture that values curiosity, comfort with ambiguity, and contributions beyond formal job boundaries. Those are the company's stated expectations, not an independent employee survey. The useful signal is that Basecamp knows it needs translators: people capable of moving between biology, engineering, computation, and development without treating organizational boundaries as scientific laws.

What Basecamp Research Has to Prove

Basecamp Research has assembled an unusual stack. It owns relationships that generate differentiated biological data, the infrastructure to process that data, models trained to design therapeutics, and a preclinical pipeline that can test whether the system creates medical value.

The defensibility sits in the integration. Competitors can train biological models. Others can collect genomic data or develop gene therapies. Basecamp's wager is that linking provenance-rich evolutionary data to model design and therapeutic execution creates an advantage that compounds.

The next evidence will not be another parameter count. It will arrive through reproducible preclinical packages, pharmaceutical partnerships, regulatory progress, and eventually human data. Basecamp Research has mapped more of biology's possibility space. Now it has to show that the map can produce directions medicine is willing to follow.